[1] |
|
[2] |
2022 Alzheimer's disease facts and figures[J]. Alzheimers Dement, 2022, 18(4):700-789. DOI: 10.1002/alz.12638.
|
[3] |
ZUIN M, RONCON L, PASSARO A,et al. Metabolic syndrome and the risk of late onset Alzheimer's disease:an updated review and meta-analysis[J]. Nutr Metab Cardiovasc Dis, 2021, 31(8):2244-2252. DOI: 10.1016/j.numecd.2021.03.020.
|
[4] |
LEE J E, SHIN D W, HAN K,et al. Changes in metabolic syndrome status and risk of dementia[J]. J Clin Med, 2020, 9(1):122. DOI: 10.3390/jcm9010122.
|
[5] |
CHO Y, HAN K, KIM D H,et al. Cumulative exposure to metabolic syndrome components and the risk of dementia:a nationwide population-based study[J]. Endocrinol Metab, 2021, 36(2):424-435. DOI: 10.3803/EnM.2020.935.
|
[6] |
AKBARALY T N, KIVIMAKI M, SHIPLEY M J,et al. Metabolic syndrome over 10 years and cognitive functioning in late midlife:the WhitehallⅡstudy[J]. Diabetes Care, 2010, 33(1):84-89. DOI: 10.2337/dc09-1218.
|
[7] |
PAL K, MUKADAM N, PETERSEN I,et al. Mild cognitive impairment and progression to dementia in people with diabetes,prediabetes and metabolic syndrome:a systematic review and meta-analysis[J]. Soc Psychiatry Psychiatr Epidemiol, 2018, 53(11):1149-1160. DOI: 10.1007/s00127-018-1581-3.
|
[8] |
CUMMINGS J, ORTIZ A, CASTELLINO J,et al. Diabetes:risk factor and translational therapeutic implications for Alzheimer's disease[J]. Eur J Neurosci, 2022, 56(9):5727-5757. DOI: 10.1111/ejn.15619.
|
[9] |
SÁIZ-VAZQUEZ O, PUENTE-MARTÍNEZ A, PACHECO-BONROSTRO J,et al. Blood pressure and Alzheimer's disease:a review of meta-analysis[J]. Front Neurol, 2023, 13:1065335. DOI: 10.3389/fneur.2022.1065335.
|
[10] |
LENNON M J, MAKKAR S R, CRAWFORD J D,et al. Midlife hypertension and Alzheimer's disease:a systematic review and meta-analysis[J]. J Alzheimers Dis, 2019, 71(1):307-316. DOI: 10.3233/JAD-190474.
|
[11] |
LENNON M J, KONCZ R, SACHDEV P S. Hypertension and Alzheimer's disease:is the picture any clearer?[J]. Curr Opin Psychiatry, 2021, 34(2):142-148. DOI: 10.1097/YCO.0000000000000684.
|
[12] |
KUEHN B M. In Alzheimer research,glucose metabolism moves to center stage[J]. JAMA, 2020, 323(4):297-299. DOI: 10.1001/jama.2019.20939.
|
[13] |
RAMIREZ A, WOLFSGRUBER S, LANGE C,et al. Elevated HbA 1c is associated with increased risk of incident dementia in primary care patients[J]. J Alzheimers Dis, 2015, 44(4):1203-1212. DOI: 10.3233/JAD-141521.
|
[14] |
LI T C, YANG C P, TSENG S T,et al. Visit-to-visit variations in fasting plasma glucose and HbA 1c associated with an increased risk of alzheimer disease:diabetes study[J]. Diabetes Care, 2017, 40(9):1210-1217. DOI: 10.2337/dc16-2238.
|
[15] |
DYE L, BOYLE N B, CHAMP C,et al. The relationship between obesity and cognitive health and decline[J]. Proc Nutr Soc, 2017, 76(4):443-454. DOI: 10.1017/S0029665117002014.
|
[16] |
GANGULI M, BEER J C, ZMUDA J M,et al. Aging,diabetes,obesity,and cognitive decline:a population-based study[J]. J Am Geriatr Soc, 2020, 68(5):991-998. DOI: 10.1111/jgs.16321.
|
[17] |
ALFORD S, PATEL D, PERAKAKIS N,et al. Obesity as a risk factor for Alzheimer's disease:weighing the evidence[J]. Obes Rev, 2018, 19(2):269-280. DOI: 10.1111/obr.12629.
|
[18] |
QIZILBASH N, GREGSON J, JOHNSON M E,et al. BMI and risk of dementia in two million people over two decades:a retrospective cohort study[J]. Lancet Diabetes Endocrinol, 2015, 3(6):431-436. DOI: 10.1016/S2213-8587(15)00033-9.
|
[19] |
GUO J, WANG J, DOVE A,et al. Body mass index trajectories preceding incident mild cognitive impairment and dementia[J]. JAMA Psychiatry, 2022, 79(12):1180-1187. DOI: 10.1001/jamapsychiatry.2022.3446.
|
[20] |
NORTON S, MATTHEWS F E, BARNES D E,et al. Potential for primary prevention of Alzheimer's disease:an analysis of population-based data[J]. Lancet Neurol, 2014, 13(8):788-794. DOI: 10.1016/S1474-4422(14)70136-X.
|
[21] |
PARDO-MORENO T, MOHAMED-MOHAMED H, RIVAS-DOMINGUEZ A,et al. Poor cognitive agility conservation in obese aging people[J]. Biomedicines, 2023, 11(1):138. DOI: 10.3390/biomedicines11010138.
|
[22] |
TANG X Y, ZHAO W, LU M,et al. Relationship between central obesity and the incidence of cognitive impairment and dementia from cohort studies involving 5,060,687 participants[J]. Neurosci Biobehav Rev, 2021, 130:301-313. DOI: 10.1016/j.neubiorev.2021.08.028.
|
[23] |
HOU Q T, GUAN Y, YU W H,et al. Associations between obesity and cognitive impairment in the Chinese elderly:an observational study[J]. Clin Interv Aging, 2019, 14:367-373. DOI: 10.2147/CIA.S192050.
|
[24] |
LUCHSINGER J A, CHENG D, TANG M X,et al. Central obesity in the elderly is related to late-onset Alzheimer disease[J]. Alzheimer Dis Assoc Disord, 2012, 26(2):101-105. DOI: 10.1097/WAD.0b013e318222f0d4.
|
[25] |
DIMACHE A M, ȘALARU D L, SASCĂU R,et al. The role of high triglycerides level in predicting cognitive impairment:a review of current evidence[J]. Nutrients, 2021, 13(6):2118. DOI: 10.3390/nu13062118.
|
[26] |
BERNATH M M, BHATTACHARYYA S, NHO K,et al. Serum triglycerides in alzheimer disease:relation to neuroimaging and CSF biomarkers[J]. Neurology, 2020, 94(20):e2088-2098. DOI: 10.1212/WNL.0000000000009436.
|
[27] |
CHEW H, SOLOMON V A, FONTEH A N. Involvement of lipids in Alzheimer's disease pathology and potential therapies[J]. Front Physiol, 2020, 11:598. DOI: 10.3389/fphys.2020.00598.
|
[28] |
ZHU Y, LIU X, ZHU R X,et al. Lipid levels and the risk of dementia:a dose-response meta-analysis of prospective cohort studies[J]. Ann Clin Transl Neurol, 2022, 9(3):296-311. DOI: 10.1002/acn3.51516.
|
[29] |
AGARWAL M, KHAN S. Plasma lipids as biomarkers for Alzheimer's disease:a systematic review[J]. Cureus, 2020, 12(12):e12008. DOI: 10.7759/cureus.12008.
|
[30] |
IQBAL G, BRAIDY N, AHMED T. Blood-based biomarkers for predictive diagnosis of cognitive impairment in a Pakistani population[J]. Front Aging Neurosci, 2020, 12:223. DOI: 10.3389/fnagi.2020.00223.
|
[31] |
WALKER J M, HARRISON F E. Shared neuropathological characteristics of obesity,type 2 diabetes and Alzheimer's disease:impacts on cognitive decline[J]. Nutrients, 2015, 7(9):7332-7357. DOI: 10.3390/nu7095341.
|
[32] |
AN Y, VARMA V R, VARMA S,et al. Evidence for brain glucose dysregulation in Alzheimer's disease[J]. Alzheimers Dement, 2018, 14(3):318-329. DOI: 10.1016/j.jalz.2017.09.011.
|
[33] |
ROJAS M, CHÁVEZ-CASTILLO M, PIRELA D,et al. Metabolic syndrome:is it time to add the central nervous system?[J]. Nutrients, 2021, 13(7):2254. DOI: 10.3390/nu13072254.
|
[34] |
MICHAILIDIS M, MORAITOU D, TATA D A,et al. Alzheimer's disease as type 3 diabetes:common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes[J]. Int J Mol Sci, 2022, 23(5):2687. DOI: 10.3390/ijms23052687.
|
[35] |
SÁNCHEZ-SARASÚA S, FERNÁNDEZ-PÉREZ I, ESPINOSA-FERNÁNDEZ V,et al. Can we treat neuroinflammation in Alzheimer's disease?[J]. Int J Mol Sci, 2020, 21(22):8751. DOI: 10.3390/ijms21228751.
|
[36] |
ROJAS-GUTIERREZ E, MUÑOZ-ARENAS G, TREVIÑO S,et al. Alzheimer's disease and metabolic syndrome:a link from oxidative stress and inflammation to neurodegeneration[J]. Synapse, 2017, 71(10):e21990. DOI: 10.1002/syn.21990.
|
[37] |
FORNY-GERMANO L, DE FELICE F G, VIEIRA M N D N. The role of leptin and adiponectin in obesity-associated cognitive decline and Alzheimer's disease[J]. Front Neurosci, 2019, 12:1027. DOI: 10.3389/fnins.2018.01027.
|
[38] |
PÉREZ-GONZÁLEZ R, ALVIRA-BOTERO M X, ROBAYO O,et al. Leptin gene therapy attenuates neuronal damages evoked by amyloid-β and rescues memory deficits in APP/PS1 mice[J]. Gene Ther, 2014, 21(3):298-308. DOI: 10.1038/gt.2013.85.
|
[39] |
MOOLDIJK S S, IKRAM M K, IKRAM M A. Adiponectin,leptin,and resistin and the risk of dementia[J]. J Gerontol Ser A Biol Sci Med Sci, 2022, 77(6):1245-1249. DOI: 10.1093/gerona/glab267.
|
[40] |
NG R C L, CHAN K H. Potential neuroprotective effects of adiponectin in Alzheimer's disease[J]. Int J Mol Sci, 2017, 18(3):592. DOI: 10.3390/ijms18030592.
|